Stanley J. Cryz mostly deals with Vaccination, Immunology, Cholera vaccine, Cholera and Virology. As a part of the same scientific family, he mostly works in the field of Vaccination, focusing on Immunity and, on occasion, Ty21a. His study in Immunogenicity, Titer and Seroconversion is carried out as part of his Immunology studies.
His biological study spans a wide range of topics, including Internal medicine, Cholera toxin and Vibrio cholerae. His Virology study frequently links to other fields, such as Microbiology. The study incorporates disciplines such as Pseudomonas aeruginosa, Elastase and Antigen in addition to Microbiology.
His scientific interests lie mostly in Immunology, Virology, Microbiology, Antibody and Vaccination. Stanley J. Cryz has included themes like Internal medicine and Cholera vaccine in his Immunology study. Stanley J. Cryz interconnects Virosome, Ty21a, Salmonella typhi and Immune system in the investigation of issues within Virology.
His research integrates issues of Antigen, Pseudomonas aeruginosa, Klebsiella, Monoclonal antibody and Conjugate vaccine in his study of Microbiology. The Antibody study combines topics in areas such as Serotype and Bacteria. His study looks at the relationship between Vaccination and fields such as Cholera, as well as how they intersect with chemical problems.
His primary areas of investigation include Immunology, Vaccination, Virology, Internal medicine and Rotavirus. In general Immunology, his work in Seroconversion, Antibody, Tetanus and Immunogenicity is often linked to Cyclophosphamide linking many areas of study. The concepts of his Vaccination study are interwoven with issues in Vibrio cholerae, Cholera vaccine, Booster dose and Ty21a.
His studies in Vibrio cholerae integrate themes in fields like Cholera and Diarrhea. His Ty21a research is multidisciplinary, incorporating elements of Immunization and Typhoid fever, Microbiology. His biological study spans a wide range of topics, including Bacterial vaccine and Monoclonal antibody.
The scientist’s investigation covers issues in Vaccination, Immunology, Seroconversion, Internal medicine and Virology. His work focuses on many connections between Vaccination and other disciplines, such as Cholera vaccine, that overlap with his field of interest in Ty21a. His Immunology study is mostly concerned with Virosome and Measles virus.
The study incorporates disciplines such as Mumps vaccine, Antibody titer, Immunoglobulin G, Immunity and Microbiology in addition to Seroconversion. His research in Antibody titer intersects with topics in Booster dose, Hemagglutination assay, Influenza vaccine and Immunogenicity. His Internal medicine research incorporates elements of El Tor, Vibrio cholerae, Cholera and Vaccine efficacy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.
MyronM. Levine;Deirdre Herrington;Genevieve Losonsky;Ben Tall.
The Lancet (1988)
Isolation and characterization of Pseudomonas aeruginosa PAO mutant that produces altered elastase.
D E Ohman;S J Cryz;B H Iglewski.
Journal of Bacteriology (1980)
Immunogenicity of new virosome influenza vaccine in elderly people.
R Glück;R Mischler;B Finkel;J.U Que.
The Lancet (1994)
Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area.
Emily Richie;Narain H Punjabi;Yuwono Sidharta;Kenny Peetosutan.
Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats.
D E Woods;S J Cryz;R L Friedman;B H Iglewski.
Infection and Immunity (1982)
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
Carol O. Tacket;Mitchell B. Cohen;Steven S. Wasserman;Genevieve Losonsky.
Infection and Immunity (1999)
Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine.
Myron M. Levine;Catterine Ferreccio;Paulina Abrego;Oriana San Martin.
Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease.
Deirdre A. Herrington;Lillian Van De Verg;Samuel B. Formal;Thomas L. Hale.
Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial
C Ferreccio;E Ortiz;S Cryz;M.M Levine.
The Lancet (1990)
Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
Suharyono;C Simanjuntak;H Totosudirjo;N Witham.
The Lancet (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: